Chinook Therapeutics (KDNY)

Chinook Therapeutics (KDNY) Stock Price & Analysis


KDNY Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$15.08 - $27.44
Previous Close$25.21
Average Volume (3M)677.18K
Market Cap
Enterprise Value$1.37B
Total Cash (Recent Filing)$350.38M
Total Debt (Recent Filing)$38.26M
Price to Earnings (P/E)-7.9
Nov 09, 2023
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.19
Shares Outstanding66,889,369
10 Day Avg. Volume613,082
30 Day Avg. Volume677,179
Standard Deviation0.22
Financial Highlights & Ratios
Price to Book (P/B)3.88
Price to Sales (P/S)922.47
Price to Cash Flow (P/CF)-11.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue261.30
Enterprise Value/Gross Profit224.24
Enterprise Value/Ebitda-6.58
Price Target Upside44.58% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7



Risk Analysis

Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products

Product Insights

Sorry, No Data Available
There is no website visitor data available for this stock.



What was Chinook Therapeutics’s price range in the past 12 months?
Chinook Therapeutics lowest stock price was $15.08 and its highest was $27.44 in the past 12 months.
    What is Chinook Therapeutics’s market cap?
    Currently, no data Available
    When is Chinook Therapeutics’s upcoming earnings report date?
    Chinook Therapeutics’s upcoming earnings report date is Nov 09, 2023 which is in 156 days.
      How were Chinook Therapeutics’s earnings last quarter?
      Chinook Therapeutics released its earnings results on May 09, 2023. The company reported -$0.85 earnings per share for the quarter, missing the consensus estimate of -$0.795 by -$0.055.
        Is Chinook Therapeutics overvalued?
        According to Wall Street analysts Chinook Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Chinook Therapeutics pay dividends?
          Chinook Therapeutics does not currently pay dividends.
          What is Chinook Therapeutics’s EPS estimate?
          Chinook Therapeutics’s EPS estimate for its next earnings report is not yet available.
          How many shares outstanding does Chinook Therapeutics have?
          Chinook Therapeutics has 66,889,366 shares outstanding.
            What happened to Chinook Therapeutics’s price movement after its last earnings report?
            Chinook Therapeutics reported an EPS of -$0.85 in its last earnings report, missing expectations of -$0.795. Following the earnings report the stock price went up 7.481%.
              Which hedge fund is a major shareholder of Chinook Therapeutics?
              Among the largest hedge funds holding Chinook Therapeutics’s share is Baker Bros Advisors LP. It holds Chinook Therapeutics’s shares valued at 34M.


                Chinook Therapeutics Stock Smart Score

                The Chinook Therapeutics stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                Learn more about TipRanks Smart Score

                Company Description

                Chinook Therapeutics

                Aduro BioTech, Inc. is a clinical-stage immunotherapy company, which engages in the discovery, development, and commercialization of therapies that transform the treatment of diseases, including cancer. Its technology platforms include STING Pathway Activator, B-select monoclonal antibody, and LADD, or Live, Attenuated, Double-Deleted Listeria monocytogenes. The company's platforms stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies like chemotherapy and radiation as well as other novel immunotherapies. Aduro BioTech was founded in 2000 and is headquartered in Berkeley, CA.


                Top 5 ETFs holding KDNY

                Market Value
                Smart Score
                Vanguard Total Stock Market ETF
                iShares Biotechnology ETF
                Vanguard Health Care ETF
                iShares Core S&P Total U.S. Stock Market ETF
                iShares NASDAQ US Biotechnology UCITS ETF
                Up to five ETFs with an Outperform Smart Score that hold KDNY. The ETFs are listed according to market value of KDNY within the ETF


                Forecast EPS vs Actual EPS

                Similar Stocks
                Price & Change
                Rocket Pharmaceuticals
                Arvinas Holding Company

                Popular Stocks

                What's Included in PREMIUM?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis